These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30017380)

  • 1. Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer.
    Berner AM; Sharma A; Agarwal S; Al-Sam S; Nathan P
    Eur J Cancer; 2018 Sep; 101():287-290. PubMed ID: 30017380
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
    Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
    Soleimani M; Nappi L; Kollmannsberger C
    Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib-ICIs boost the RCC armamentarium.
    Romero D
    Nat Rev Clin Oncol; 2019 Apr; 16(4):207. PubMed ID: 30833679
    [No Abstract]   [Full Text] [Related]  

  • 5. Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma.
    Yang Y; Huang H; Li T; Gao Q; Song Y; Wang Z
    Front Immunol; 2021; 12():728750. PubMed ID: 34764951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous collagenous vasculopathy induced by the vascular endothelial growth factor receptor inhibitor axitinib.
    Matsuzaki Y; Takahashi M; Minakawa S; Jin K; Nakano H; Sawamura D
    Int J Dermatol; 2018 Dec; 57(12):e167-e169. PubMed ID: 30229881
    [No Abstract]   [Full Text] [Related]  

  • 7. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
    Wallin JJ; Bendell JC; Funke R; Sznol M; Korski K; Jones S; Hernandez G; Mier J; He X; Hodi FS; Denker M; Leveque V; Cañamero M; Babitski G; Koeppen H; Ziai J; Sharma N; Gaire F; Chen DS; Waterkamp D; Hegde PS; McDermott DF
    Nat Commun; 2016 Aug; 7():12624. PubMed ID: 27571927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role.
    Eisen T
    Eur J Cancer; 2015 Nov; 51(17):2578-9. PubMed ID: 26613659
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers to predict prognosis and response to checkpoint inhibitors.
    Yuasa T; Masuda H; Yamamoto S; Numao N; Yonese J
    Int J Clin Oncol; 2017 Aug; 22(4):629-634. PubMed ID: 28382562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal Pneumatosis: A Manifestation of Rarely Reported Axitinib-Associated Necrotizing Enterocolitis.
    Akhtar K; Zayac A; Lemke S
    Am J Ther; 2018; 25(6):e763-e765. PubMed ID: 29746290
    [No Abstract]   [Full Text] [Related]  

  • 14. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
    Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
    Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
    Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
    Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in lung cancer: an update.
    Sullivan K; Preeshagul I; Budman D; Seetharamu N
    Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibody therapy of kidney cancer.
    Oosterwijk E; Brouwers A; Boerman OC; Larson SM; Old LJ; Mulders P; Divgi CR
    Cancer Treat Res; 2003; 116():199-212. PubMed ID: 14650834
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G; Generali D
    Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.